Founded in 2008, Recombinetics focused its early-stage development on the application of precision genetic technologies in animals and active patent filings.
Today, Recombinetics is widely recognized as the leader in livestock gene-editing and associated applied technologies for biomedical research, regenerative medicine, and animal agriculture.
We have a rich history as innovators and early adopters of molecular tools and methods for animal gene editing enhanced by incorporation of artificial intelligence. When paired with our experienced teams focused on bioinformatics, cell engineering, stem cell biology, and preclinical research, we’re able to add value to livestock and make pivotal changes in human health and longevity.
Recombinetics’ ever-expanding pipeline of gene-edited animals, products, and preclinical services, position the company for rapid growth in biomedical and food animal markets
As leaders in the gene editing space, our global patent portfolio has grown to include potent gene editing methods and compositions with broad coverage for non-human species.
First commercial launch of swine reporter models for gene therapy development.
First swine reporter models validated for in vivo gene editing.
First swine reporter models validated for in vivo gene therapy delivery;
First preclinical test performed in Therillume brain tumor models.
First generation swine reporter models produced.
First inducible brain cancer models developed – foundation of Therillume.
First inducible liver cancer models developed.
First to develop several pig models, including Neurofibromatosis Type 1 and Type 2, Ostogenesis imperfecta, and polycystic kidney disease;
Discovery of new mechanism for human dilated cardiomyopathy in novel pig model;
First to make APOBEC pigs for PERV-safe organs.
First patent allowance for multiplex gene editing in primary markets of USA and Brazil.
First to develop serial multiplex editing in porcine stem cells.
First to develop serial multiplex editing in bovine stem cells.
First demonstration of in vivo somatic gene transfer in swine.
First patent issued in China for gene editing large animals;
First patent issued in Europe for gene editing large animals.
First patent issued in the US for CRISPR gene editing in animals.
First TALENs use to knockout and break genes in embryos.
SLICK Angus progeny are born and raised in US.
FDA allows commercial use of first two SLICK Angus;
First Thamani Holstein is born derived from editing of multiple traits in bovine embryonic stem cells.
First non-GMO decision for heavy muscled Nelore bull in Brazil.
Bred first commercial slick Angus in US using CRISPR/Cas9 in embryos.
Demonstrated heat tolerance of SLICK for Angus clone in Brazil (bred by TALENs).
Demonstrated durability of polled trait bred by gene editing.
First polled dairy animal prototype bred by TALENs (first HDR edited bovine – first use of gene editing in cattle as validation of non-genic variation for polled trait).
Bred heavy muscled Nelore bull by embryo treatment with TALENs (first bovine animal edit).
Our scientific findings are often published in peer-reviewed scientific journals and often cited by other scientists in their published research. Our Scientist are highly published and have been involved in over 74 publications, while employed at Recombinetics. See the link below for some of our highlights.